This document is a printout of an article, likely from Forbes circa 2015, discussing a new cholesterol drug, Praluent. The article details the drug's effectiveness, its high cost ($14,600/year), and the companies involved, such as Regeneron, Sanofi, and Amgen. Although the document has a 'HOUSE_OVERSIGHT' Bates number, its content does not contain any explicit mention of Jeffrey Epstein or related individuals, and its relevance to that case is not apparent from the text itself.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity